In vivo studies demonstrated that TNF-α-loaded exosome-based vehicle delivery enhanced cancer targeting under an external magnetic field, leading to enhanced antitumor efficacy and reduced systemic toxicity [46]. The gene discussed is TNF; the disease is cancer.